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Retinaldehyde dehydrogenase II (RalDH2) converts
retinal to the transcriptional regulator retinoic acid in
the developing embryo. The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases
of the same enzyme superfamily; a 20-amino acid span in
the substrate access channel in retinaldehyde dehydrogenase II is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of
the substrate access channel. We asked whether this
disordered loop might order during the course of catalysis and provide a means for an enzyme that requires a
large substrate access channel to restrict access to the
catalytic machinery by smaller compounds that might
potentially enter the active site and be metabolized. Our
experiments, a combination of kinetic, spectroscopic,
and crystallographic techniques, suggest that a disorder
to order transition is linked to catalytic activity.

In the developing embryo the generation of retinoic acid by
metabolism of the inactive precursor retinol must be finely
regulated. The consequences of deregulation of this process are
tragic; the teratogenic effects of retinoic acid analogs used to
treat cystic acne are thought to be a result of aberrant retinoic
acid concentrations during morphogenesis (1). In their studies
of the developing spinal cord, McCaffery and Drager (2) observed retinal dehydrogenase activity with the same spatiotemporal distribution as that of retinoic acid and subsequently
identified the enzyme retinaldehyde dehydrogenase type II
(RalDH2)1 in their examination of the effect of retinoic acid
signaling in the formation of the neural axis (3). Similar studies
suggested a role for RalDH2 in the developing mammalian
heart (4). The validity of the hypothesis that RalDH2 produces
retinoic acid in the developing embryo was confirmed by the
transgenic knock-out mice results of Chambon and co-workers
(5). RalDH2⫺/⫺ embryos exhibit the spectrum of defects associated with developmental processes previously shown to be
retinoic acid-dependent and die at mid-gestation. Near full
rescue is observed when retinoic acid is administered to the
mothers (5). These results provide a striking contrast to those
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of similar experiments in which the different retinoic acid
receptor genes were mutated in mice. Six genes code for two
classes of retinoic acid receptors in the mammalian genome,
and the inactivation of a single gene for a retinoic acid receptor
results in only mild abnormalities in developmental phenotypes (6, 7). However, RalDH2 activity is indispensable in
morphogenesis (5). Prior to this work, RalDH2 was cloned by
the Napoli laboratory as a result of their efforts to identify
enzymes that produced retinoic acid in the testis (8). Retinoic
acid is abundant in the testis, and the use of that tissue avoided
the complications of using liver as a source for cDNA. The liver
has many more abundant aldehyde dehydrogenases, such as
the phenobarbital-inducible dehydrogenases, which would
complicate the identification of the retinaldehyde-specific dehydrogenase. In the adult animal RalDH2 is expressed in brain
and lung as well as the testis (8).
RalDH2 is a member of the NAD-dependent aldehyde dehydrogenase (ALDH) superfamily for which there are several
structures available in addition to that of RalDH2 (9 –13).
Those structures of the enzyme from bovine mitochondria and
sheep liver have the highest sequence identity with RalDH2
(66 and 73% identity, respectively). A structure for the highly
homologous lens protein -crystallin (70% identity) has been
described recently (14) as well. Aldehyde dehydrogenases utilize a conserved Cys (Cys-302 in the bovine mitochondrial
enzyme) in the oxidation of aldehyde to carboxylic acid with the
concomitant reduction of NAD to NADH. RalDH2 is able to
process retinal free or as it is found in the cell bound to its
carrier protein cellular retinol/retinal binding protein (8).
Many aldehyde dehydrogenases are classed as detoxification
enzymes as the enzymes selectively eliminate aldehydes generated in the metabolism of xenobiotics and endogenous compounds. However, the knock-out experiments described above
clearly demonstrate that RalDH2 is the source of retinoic acid
required for normal development and consequently indicate a
pivotal role for the enzyme in the production of the transcriptional regulator retinoic acid.
The structures of aldehyde dehydrogenases involved in the
metabolism of acetaldehyde have a long (⬃18Å) substrate access channel into which acetaldehyde can readily diffuse. However, retinal dehydrogenase differs in that it has a disordered
loop within the substrate access channel, and it was suggested
that it is precisely this disorder (13) that is key to the fact that
substrate preference of RalDH2 is for long aliphatic aldehydes
(8). A substrate-induced disorder to order transition was proposed to mediate substrate recognition. Hurley et al. (15) subsequently reported a disorder to order transition induced by the
binding of the co-factor to the bovine mitochondrial ALDH2:
R475Q mutant that involves the same region of that enzyme,
but in RalDH2 with co-factor bound this region remains disordered as indicated by the lack of any interpretable electron
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density in an otherwise clear electron density map. We report
here a series of experiments designed to reveal the functional
basis for the lack of a well formed substrate access channel in
RalDH2. We asked whether access channel disorder might
provide a mechanism for the enzyme, which requires a large
substrate binding channel for its 20-carbon biological substrate, to restrict access to catalytic machinery by smaller
aldehydes. This mechanism could be a result of the linking of a
disorder to order transition to catalytic activity.
We reasoned that regions of a protein that are disordered
and do not participate directly in catalysis or substrate binding
are insensitive to amino acid substitutions. If we introduce
mutations into a region of the disordered loop and observe a
reduced catalytic activity that cannot be explained by a loss in
substrate binding affinity, then we can infer that the segment
of the polypeptide in which the mutation was made makes a
specific intramolecular interaction during the catalytic cycle,
i.e. a disorder to order transition occurs. This is precisely what
we observe; mutation of the disordered segment results in a
reduced apparent Vmax for the enzymatic reaction catalyzed
by RalDH2.
Fluorescence data support our interpretation of the experimental results. In the region of the disordered loop there are
two Trp residues (Trp-176 and Trp-451). If the loop adopts a
conformation similar to the corresponding region of the homologous aldehyde dehydrogenases, these tryptophans would be
shielded from solvent. An additional Trp (Trp-167) packs
against the ribose ring in the NADH binding site. We observed
a reduced fluorescence resonance energy transfer between Trp
and NADH that accompanies catalysis in RalDH2 in which
amino acids substitutions are introduced in the disordered loop
region. Such an observation would be expected if the loop
mutant were incapable of ordering in the access channel and
shielding Trp-176 and Trp-451 from solvent, or if the position
or environment of the nicotinamide ring were affected. Steady
state kinetic data indicate that the affinity for a series of model
substrates is not significantly affected by the amino acids substitutions. In contrast, the Km for the co-factor NAD is appreciably higher in the mutant enzyme despite the fact that the
substitution was made in the access channel and removed from
amino acids that directly interact with co-factor. These observations suggest non-local structural consequences of the mutation, consistent with a disorder to order transition.
In addition, we determined the crystal structure of the mutant enzyme in the presence of NAD and absence of substrate
and show that it is essentially unchanged from the native
structure; the “disordered loop” of the access channel is disordered in the presence of NAD and absence of substrate just as
it is in the wild-type enzyme. Thus an inadvertent ordering of
the loop can be ruled out.
EXPERIMENTAL PROCEDURES

Bacterial Strains and Media—The expression strain E. coli
BL21(DE3) pLysS from Novagen was used to overexpress all RalDH2
constructs. For all growths and protein overexpression, LB (10.0 g of
casein, 5.0 g of yeast extract, and 10.0 g of NaCl, pH 7.0) was used.
Novablue (Novagen) and XL1-Blue (Stratagene) cells were used for the
cloning and propagation of all plasmid constructs. The antibiotics ampicillin and chloramphenicol were used at final concentrations of 50 and
34 g/ml, respectively, when used in either broth or 1.5% agar plates.
Construction of an Expression Plasmid for Non-histidine-tagged
Wild-type RalDH2—The gene for mouse RalDH2 maintained in the
Invitrogen cloning vector pCDNA3 was a gift from Dr. J. L. Napoli. PCR
was performed to amplify the entire RalDH2 gene from plasmid
pCDNA3. PCR product was cloned into plasmid pSTBlue1 using the
Perfectly Blunt cloning kit (Novagen). The RalDH2 gene was subsequently excised via an NdeI/BamHI digestion and ligated into the
Novagen pET3a vector to yield the RalDH2 expression plasmid pTBRD2, in which RalDH2 gene expression is regulated by the T7

promoter. Plasmid pTBRD2 was sequenced to ensure that no point
mutations were introduced during PCR. Mouse RalDH2 has a single
amino acid change from rat (I352V, mouse 3 rat), the source of the
clone for our previous structure determination.
Site-directed Mutagenesis—The RalDH2 double mutant L459F/
N460G and catalytic mutant C301A were constructed via the
QuikChange site-directed mutagenesis kit (Stratagene) using plasmid
pTBRD2 as the template. The resulting plasmids, pTBRD2FG and
pTBC301A, were sequenced to confirm the presence of the mutations
within the RalDH2 gene and to confirm that no extraneous mutations
had been introduced through PCR.
Expression and Purification of Mouse RalDH2—For expression of the
RalDH2 constructs, plasmids were transformed into E. coli BL21(DE3)
pLysS. An overnight culture was grown to saturation followed by a
100-fold dilution into 1 liter of LB containing ampicillin and chloramphenicol. The culture was grown at 37 °C with continuous shaking (220
rpm) until the A600 reached 0.8 and isopropyl-␤-D-thiogalactopyranoside
was added to a final concentration of 0.5 mM to induce RalDH2 expression. The culture was then grown for an additional 1 h after induction
under the same conditions followed by an additional 48 h of incubation
carried out at room temperature with constant agitation (220 rpm).
Cells were harvested by centrifugation at 6,000 ⫻ g for 10 min at 4 °C
and were subsequently resuspended in low salt buffer (25 mM KCl, 1 mM
EDTA, 2 mM ␤-mercaptoethanol, and 20 mM HEPES, pH 8.4) at a
concentration of 35 ml per 1 liter of bacterial culture and then frozen at
⫺80 °C. Cells were lysed with three cycles of freezing and thawing of
the cell suspension. DNase and MgCl2 were added at a final concentration of 40 Kunitz units and 5 mM, respectively, per 35 ml of cell
suspension to degrade chromosomal DNA. Protease inhibitors pepstatin and leupeptin were also added to the lysate to help prevent proteolytic cleavage of RalDH2. The crude lysate was centrifuged at 25,000 ⫻
g for 1 h at 4 °C. All further protein purification steps were conducted
at 4 °C. The supernatant was removed and diluted 2-fold with low salt
buffer and then applied to a column containing 70 ml of Affi-Gel Blue
Gel in which RalDH2 was able to bind to the column via its nucleotide
binding domain. The column was thoroughly washed with a NaCl step
gradient (25 mM, 500 mM, and 1 M NaCl) using 3 column volumes of low
salt buffer supplemented with the corresponding amounts of NaCl.
RalDH2 was then eluted with 2 column volumes of low salt buffer
containing 2 mM NAD. The eluant was concentrated to 5–7 ml using
Amicon Ultra centrifugal filter devices. Glycerol was added to the
concentrated protein to a final concentration of 10%, and the sample
was applied to an S300 Sephacryl sizing column. Further purification
was achieved by anion exchange chromatography on a 7.5-ml DEAE
cellulose column eluted with a NaCl gradient. Purified enzyme was
concentrated to 10 mg/ml and analyzed by SDS-PAGE for protein purity
before dropwise flash freezing in liquid nitrogen and storage at ⫺80 °C.
Crystallization—Crystals were grown in hanging drop vapor diffusion experiments. Drops were 2 l of RalDH2:L458F/N459G (7.6 mg/ml)
in the presence of excess NAD (2 mM) and retinol (at 1.8 times the
concentration of enzyme) plus an equal volume of well solution (7% PEG
6000, 2% 2-methyl-2,4-pentanediol, and 0.1 M Tris, pH 7.5). The crystals
belong to space group P21 and have unit cell dimensions of a ⫽ 83.32 Å,
b ⫽ 142.03 Å, c ⫽ 85.00 Å, ␤ ⫽ 93.88°. There is one tetramer in the
asymmetric unit.
Data Collection and Structure Determination—Crystals of the
RalDH2 loop mutant were transferred directly to mother liquor supplemented with 20% glycerol and frozen in the stream of an Oxford Cryojet. X-ray data were collected with a Mar345 image plate scanner
mounted on a Nonius FR591 generator fitted with Osmic mirrors. A
total of 177 frames of 1° oscillations were collected to give a 3.3 Å
resolution data set with a final Rmerge of 14.0%. The data set is 95.3%
complete (72% in the highest shell) with 3.2-fold redundancy. At this
resolution the overall I/ was 9.5 (1.8 in the highest resolution shell).
The structure was solved by the method of molecular replacement. A
tetramer of the native structure of rat RalDH2 served as a search model
(13). The resulting 3.3 Å resolution structure was refined with 4-fold
non-crystallographic symmetry constraints to a Rwork (Rfree) of 0.229
(0.304) with no  cutoff applied to the reflections. The model includes
14,571 protein atoms, 108 co-factor atoms (only the adenine diphosphate is positioned), and 39 water molecules. Average protein, co-factor,
and water B-factors are 61, 45, and 65 Å2, respectively. Diffraction data
were processed with Denzo and Scalepack (16). All other crystallographic calculations were performed with CNS (17). Maps were interpreted with the program O (18).
Kinetic Measurements—Enzyme assays for the determination of the
Km values of the substrates were conducted over at least six substrate
concentrations (4 to 250 M for hexanal, octanal, and decanal and 1 mM
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to 128 mM for acetaldehyde) in an Applied Photophysics stopped-flow
reaction analyzer by monitoring NADH fluorescence (excitation wavelength 340 nm, emission cutoff filter 420 nm) with a 0.2-cm path length.
These experiments were performed at 25 °C. Enzyme activity was
quantitated for each set of experiments by monitoring the absorbance of
NADH at 340 nm in the stopped-flow. Measurements were performed at
either 230 or 460 nM enzyme in the presence of 1 to 4 mM NAD, 10 mM
HEPES, pH 8.5, 150 mM KCl, 1 mM EDTA, and 2 mM ␤-mercaptoethanol. These concentrations are those in the observation cell. Each
experimental trace in fluorescence mode is the average of three consecutive observations. For absorbance mode data, at least eight traces
were averaged.
The activity of the dual mutant enzyme for retinal was compared
with that of the wild-type enzyme by monitoring fluorescence changes
under identical assay conditions. When retinal (which absorbs at 340
nm) is the substrate, care is taken to avoid quenching of the fluorescence by performing the measurements at concentrations of retinal
with an absorbance of less than 0.1. We found that the mutant had 34%
of the activity of the wild-type enzyme under identical assay conditions,
but given the spectral properties of retinal we were unable to determine
whether the apparent reduction in the rate of retinal oxidation could
not be overcome at higher substrate concentrations as the absorbance
properties of retinal and retinoic acid interfered with our assay at
higher substrate concentrations.
The data for the NAD Km determinations were obtained by monitoring the absorbance of NADH with an Agilent diode array spectrophotometer with octanal (50 M) as the substrate. Data were obtained for
six concentrations (in triplicate, 0.125– 4 mM NAD for the mutant).
Data Analysis—Values for Km and Vmax were determined by nonlinear regression analysis of a plot of velocity versus substrate (or NAD)
concentration data to the Michaelis-Menten equation. For the acetaldehyde data with the mutant enzyme the data fit best to equation (1),
where V1 and V2 are maximal velocities, Km1 and Km2 are Michaelis
constants, and A is the concentration of substrate.
v ⫽ V 1A/共K m1 ⫹ A兲 ⫹ V 2A共K m2 ⫹ A兲

(Eq. 1)

Fluorescence Spectra—Fluorescence emission spectra of proteinbound (in the absence of substrate or product) and free NADH were
recorded at excitation wavelengths of 295 nm and 340 nm in a Jasco
FP-6300 fluorimeter. For these spectra, enzyme was incubated with an
excess of NADH and desalted with Sephadex G-25 prior to
the measurements.
Fluorescence Changes in the Pre-steady State Regime—The change in
florescence that occurs upon mixing of substrate and enzyme as above
was monitored by excitation at 295 nm in an Applied Photophysics
stopped-flow reaction analyzer. The cutoff filter used for these measurements was 420 nm. The observed NADH fluorescence has two components: fluorescence that is caused by absorbance by NADH at 295 nm,
and that emission that occurs as a result of energy transfer from the
excited Trp residues within the Förster distance of NADH. Experiments
were performed with a catalytically inactive mutant (RalDH2:C301A)
as well as the native and loop mutant proteins. No signal is observed for
the catalytically inactive mutant. Because this enzyme is incapable of
producing NADH, the lack of a signal is consistent with our interpretation that the fluorescence observed is that of NADH, which results
from either resonance energy transfer from Trp or from NADH absorbance at 295 nm. These experiments were performed with 460 nM enzyme, 4 mM NAD, 250 M octanal in the observation cell.
RESULTS AND DISCUSSION

The structure of RalDH2 was determined previously in the
presence of NAD and the absence of substrate or substrate
analog. Amino acids ⬃457– 477 were not visible in the electron
density maps (13) and unlike their counterparts in the previous
ALDH structures, which were also determined in the presence
of co-factor but absence of substrate (9 –12, 15) were disordered.
(Alternatively, these regions may have more than one possible
conformation, and these conformations could be randomly distributed in the tetramer of the asymmetric unit.) In contrast to
what is observed for ALDH2 and ALDH3, retinaldehyde dehydrogenase type II shows preference for aldehydes with long
hydrocarbon chains in vitro and does not efficiently oxidize
acetaldehyde (8). These data led us to propose a model for how
disorder in this region might determine substrate specificity;
the disordered loop provides a mechanism to link substrate
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binding to catalysis. We reasoned that the binding of a large
hydrophobic substrate such as retinal induces a conformational
change that orders the loop and enables catalysis. Smaller
aldehydes are unable to promote this conformational change
because they lack sufficient surface for productive interaction.
Implicit in this model is the idea that the channel must order
(no matter what the substrate) for optimal catalytic activity. To
test this theory we chose to introduce two mutations in the
mobile loop: residues Leu-458 and Asn-459 were replaced by a
Phe and Gly, respectively, their counterparts in the highly
homologous bovine mitochondrial dehydrogenase (10). Studies
with this enzyme by others have provided an enormous amount
of mechanistic information that we can utilize to guide our
interpretation of data obtained for RalDH2 (10, 19 –26).
The mutated amino acids (458 – 459) are located at the amino-terminal end of the disordered loop region and in the homologous structures form a surface at the base of the substrate
access channel. The catalytic Cys (Cys-301 in RalDH2) is between the wall of the access channel that Phe-459 provides and
the NAD binding site. The three-dimensional context of the
mutation is highly conserved between RalDH2 and ALDH2,
and in the latter enzyme the corresponding Phe participates in
an aromatic cluster with amino acids found in RalDH2 as well
(Trp-177 and Phe-465; ALDH2 numbering). Multiple reasons
are behind the choice of this dual substitution (1). This sequence difference between RalDH2 and ALDH2 (LN versus FG)
could conceivably be one of the reasons that the channel is
disordered in the former but ordered in the latter enzyme. Both
Phe and Gly could contribute to stabilization of the loop in
ALDH2 as Phe participates in the aromatic cluster referred to
above, and Gly appears to be required for its lack of a side
chain. In such a case the introduction of the substitutions
might order the channel, and this result would allow us to
determine the consequence of a “permanent” ordering (versus
“permanent” disordering) of the loop on catalysis (2). It is
important to emphasize here that the disordered loop is not
fully surfaced-exposed but confined in the volume of the access
channel. Thus in its disordered state, the loop region may
represent a mobile barrier that smaller substrates must circumnavigate to reach the catalytic cysteine. A dual substitution was required to ensure no net gain in the volume of amino
acids that must be accommodated in the channel (3). The
mutated positions are removed in sequence from Ser-470, an
invariant amino acid (Ser-471 in ALDH2 numbering) that has
been shown to be important in this superfamily of enzymes. A
substitution of an immediate neighbor of this amino acid could
conceivably interfere directly with enzyme activity. In Fig 1a,
the structure of ALDH2 with NADH bound as reported by
Perez-Miller and Hurley (27) is provided to illustrate the above
points. Amino acids that are identical in the two enzymes are
shown in green.
Confirmation That Native-like Structure Is Maintained in
the Mutant Protein—To confirm that the introduction of the
mutations did not result in unanticipated structural changes or
inadvertently order the otherwise disordered loop, we determined the structure of the mutant enzyme to 3.3 Å resolution.
Although this resolution is modest, it is sufficient to confirm
that the structure of the L458F/N459G mutant is indeed native-like and that the loop comprised of amino acids 457– 477
remains disordered in the enzyme. In addition, the electron
density for the catalytic residues is poor. The quality of this
density was also marginal in the original histidine-tagged wildtype structure (13). The wild-type and L458F/N459G monomer
structures superimpose with a root mean square deviation of
0.76 Å for 470 C␣ values. Structural agreement is better in the
NAD binding domain (root mean square deviation 0.44 Å for
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FIG. 1. The structure co-factor binding site of ALDH2 and a comparison of RalDH2 and ALDH2 structures. a, the active site of ALDH2
with two conformations of reduced co-factor as described by Perez-Miller and Hurley (27) (Protein Data Bank accession code 1O00). Amino acids
that are identical in RalDH2 and ALDH2 are shown in green. Those unique to ALDH2, which include the double mutation introduced into RalDH2,
are shown in pink. The “loop” not apparent in the RalDH2 structures is shown in yellow. b, overlay of dimers of the structures of RalDH2:L458F/
N459G (orange and pink), wild-type RalDH2 (gray) (Ref. 13), and ALDH2 (black) (Ref. 10). c, superposition of the NAD (red) binding sites of the
wild type (blue) and RalDH2:L458F/N459G (green). The structure of the NAD binding domain in the mutant enzyme revealed no structural
changes in this area.

250 C␣ values) than the catalytic domain (0.78 Å for 204 C␣
values). An overlay of the structures is presented in Fig 1b,
along with a detail of the NAD binding site that is representative of the structural identity observed for the wild-type and
mutant enzymes throughout the structures in 1c. In both structures, crystallized in the presence of NAD, only the adenine
dinucleotide portion of the co-factor is visible, consistent with
what has been observed for other ALDH structures (e.g. Ref.
10). The backbone trace of ALDH2 (10) is included in Fig. 1b so
that the structure adopted by other aldehyde dehydrogenase in
the loop region 457– 477 is illustrated.
The Introduction of Mutations in the Disordered Loop Affects
Enzyme Activity—Steady state enzyme activity was measured
over a range of substrate concentrations for the model substrates decanal, octanal, hexanal, and acetaldehyde to evaluate
the effect of the mutation on catalytic activity. In contrast to
site-directed mutagenesis studies aimed at identifying amino
acids that directly participate in enzyme catalysis or substrate
binding, these experiments probe whether certain amino acids
are required to maintain the structure of the active site, i.e. we
are simply using enzyme activity assays to determine whether
enzyme structure has been affected. Therefore, we expect to see
only modest changes in enzyme activity consistent with an
altered local geometry of the active site. When compared with
the wild-type enzyme, RalDH2:L458F/N459G shows a decrease
in catalytic activity for decanal, octanal, and hexanal that
cannot be explained by a loss of substrate affinity as the Km
values for the model substrates have not been adversely affected. The results of these experiments are summarized in
Table I.

It appears that the substitution of Phe-Gly for Leu-Asn in
the disordered loop prevents this peptide from adopting a fully
functional conformation in the three-dimensional structure.
Thus, the introduction of amino acid changes that do not form
part of the catalytic machinery results in impaired catalytic
activity, and a disorder to order transition must occur for
effective catalysis. The substrate channel must become ordered
for optimal catalysis (even for substrates that do not fill the
access channel), and the mutations prevent the loop from making this disorder to order transition. In both the mutant and
wild-type enzymes, the catalytic residues are mobile as inferred from the fact that the electron density for these amino
acids is poor. If ordering of the loop has non-local structural
consequence (as we show below with respect to the NAD binding site) then ordering of the loop could be linked to stabilization of the functional conformation of the catalytic residues.
As described above, acetaldehyde is a very poor substrate for
RalDH2. It is straightforward to reconcile this low activity with
our suggestion that a substrate induced disorder to order transition is required for optimal activity; the two-carbon substrate
is just too small to invoke the conformational change necessary
to optimally order the catalytic machinery. The mutant enzyme
RalDH2:L458F/N459G has 66% of the activity for acetaldehyde
of the wild-type enzyme over a concentration range of 0.250 –32
mM substrate. However, the data for the mutant enzyme exhibit negative cooperativity; the data fit best to a double rectangular hyperbola based of the fact that the average least
squares of the residuals were the lowest for Equation 1. It is
interesting to note that Vmax (1) for the mutant enzyme is
equivalent to the Vmax of the wild-type enzyme. This might
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TABLE I
Kinetic parameters
Kinetic parameters for substrates were determined by monitoring the steady state rate of NADH production by fluorescence. Measurements
were performed in an Applied Photophysics stopped-flow reaction analyzer by varying aldehyde concentrations at fixed NAD concentrations (1– 4
mM after mixing). The corresponding values for the NAD co-factor were determined by monitoring NADH absorbance at 340 nm over a range of
NAD concentrations with octanal as the substrate (100 M). Km and Vmax values with their standard errors were determined by non-linear
regression analysis in Sigmaplot. The data for the mutant enzyme with acetaldehyde as a substrate exhibit negative cooperativity, and
consequently two values for both Vmax and Km are reported.
Wild type

RalDH2:L458F/N459G

Substrate
Vmax

Km

Vmax

nmol/min/mg

Decanal
Octanal
Hexanal
Acetaldehyde
NAD

960 ⫾ 25
1080 ⫾ 130
820 ⫾ 20
650 ⫾ 140

Km

nmol/min/mg

1 ⫾ 0.2 M
10 ⫾ 0.6 M
5 ⫾ 0.3 M
14 ⫾ 6 mM
67 ⫾ 10 M

510 ⫾ 120
390 ⫾ 20
690 ⫾ 20
630 ⫾ 85
31 ⫾ 5

1 ⫾ 0.2 M
5 ⫾ 0.6 M
8 ⫾ 0.7 M
31 ⫾ 5 mM
0.14 ⫾ 0.07 mM
390 ⫾ 36 M

FIG. 2. Enzyme activity monitored by the production of NADH. A linear rate of NADH production is observed when the absorbance of
NADH is monitored at 340 nm (A340) (left panel, wild-type enzyme; right panel, RalDH2:L458F/N459G). These data correspond to the standard
reaction conditions of 460 nM enzyme, 4 mM NAD in assay buffer (see under “Experimental Procedures”). The reaction is initiated with the mixing
of substrate (in this case 250 M hexanal).

suggest that the catalytic machinery is disordered in both
enzymes, as one might predict from a substrate induced order
to disorder transition that must be induced by the binding of a
large hydrophobic substrate. Neither the mutant nor wild-type
enzyme is able to achieve an ordered structure of the loop with
such a small substrate. However, the mutant enzyme displays
negative cooperativity, indicative of communication between
subunits, whereas the wild-type enzyme does not. Note that in
Fig. 1b, it is clear that if the loop is positioned as it is in the
homologous ALDH2 it lies at the dimer interface and loop
conformation in one protomer could have structural consequences in its mate, consistent with the need for intersubunit
communication. Our data do not rule out a more trivial explanation for the apparent difference. These experiments are done
at high concentrations of acetaldehyde (mM), and the mutant
enzyme may simply be more susceptible to inactivation by
acetaldehyde covalent modification. It is interesting to note
that the loop region has been implicated in intersubunit communication in terms of the dominant negative effect of a mutation of R475Q in ALDH2 (15, 28). Our steady state kinetic
data indicate that the mutant enzyme has a reduced catalytic
activity and that this reduction in activity is not a consequence
of impaired substrate affinity. Steady state rates, however,
could be affected by changes in the rate of product or NADH
release. Accordingly, we obtained pre-steady state data by
measuring the absorbance of NADH produced for both the
wild-type and loop mutant enzymes and observed a linear rate
(Fig. 2). This observation suggests that the changes in catalytic
activity we measure reflect changes in reaction rates for a step
prior to or concomitant with the production of NADH monitored, i.e. substrate binding or attack or hydride transfer.

Therefore what we observe is not a consequence of a lowered
rate of product release.
Fluorescence spectra and changes that accompany catalysis
provide experimental data to support a disorder to order conformational change. RalDH2 has six Trps per monomer, and
three are in the immediate vicinity of the nicotinamide ring as
positioned by Perez-Miller and Hurley in ALDH2 (27). Of particular in interest are Trp-176 and Trp-451 in RalDH2, which
in our structure with the mobile loop are exposed to solvent in
the access channel. In the homologous enzyme ALDH2, solvent
access to the corresponding tryptophans is restricted by the
now ordered loop that covers them. In ALDH2, the counterpart
for Trp-176 (Trp-177) forms part of an aromatic cluster with
Phe-458 (Phe-459 in ALDH2 numbering) (Fig. 1a) and is ⬃8 Å
from the nicotinamide ring as positioned in ALDH2, whereas
the counterpart for Trp-451 is wedged between a Val and a Leu
and ⬃10 Å from the co-factor. Assuming a similar loop conformation is adopted in RalDH2, we looked to see if changes in Trp
fluorescence might accompany substrate binding. In addition
to the tryptophans in the vicinity of the mobile loop, there is an
interaction of Trp-167 with the ribose ring of the NAD co-factor.
The three tryptophan (Trp-167, Trp-176, and Trp-451) NADH
distances are all within the Förster distance of 25 Å (29) for
resonance energy transfer for this donor (Trp) and acceptor
(NADH) pair to occur.
Fluorescence emission spectra of NADH in the absence and
presence of enzyme (in the absence of substrate and product)
clearly reveal an enhanced NADH signal at the excitation
wavelength for Trp (Fig. 3) when NADH is protein bound and
thus indicate Trp to NADH fluorescence resonance energy
transfer. Upon mixing enzyme:NAD with substrate, a large
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FIG. 3. Fluorescence (F) emission spectra of NADH in the presence and absence of enzyme at excitation wavelengths of 295 and
340 nm. Note that when NADH is free in solution (left panel) the emission at the excitation wavelength of 295 nm is ⬃33% (as determined from
the area under the curve) of that when the excitation wavelength is 340 nm. In contrast, when NADH is bound to RalDH2 (right panel) in the
absence of substrate the emission at the excitation wavelength of 295 nm is ⬃63% of that observed for an excitation wavelength of 340 nm.

increase in fluorescence at the excitation wavelength for Trp
(295 nm) is observed for the wild-type enzyme (Fig. 4) This
increase is twice that observed at the excitation wavelength of
NADH. Similar experiments with RalDH2:L458F/N459G produce a signal ⬃50% of that for the wild type, but again the
fluorescence recorded at the excitation wavelength of Trp is
approximately twice that observed for the NADH excitation
wavelength. The fluorescence signal we observe is that which
passes through the 420-nm cutoff and can be attributed to
emission by NADH as a result of resonance energy transfer
from the excited Trp and/or emission by NADH caused by its
absorbance properties at 295 nm. We performed the same
measurements with a C301A mutant. The catalytic cysteine is
invariant in this family of enzymes, and Farres et al. (19) have
demonstrated that its mutation to alanine in a highly homologous ALDH yields an inactive enzyme that is able to bind
co-factor. Our C301A binds co-factor as well, as during the
purification it 1) binds a dye affinity column and is eluted with
NAD and 2) elutes from a sizing column with bound NAD.
RalDH2:L458F/N459G displays a dramatically reduced fluorescence signal, and C301A under identical assay conditions
produces none. These observations may indicate that NADH is
serving as an intrinsic fluorescent probe, and the decrease in
the signal for the double mutant is a result of a conformational
difference which results in altered fluorescent properties. No
signal is observed for the C301A because no NADH is produced.
There is ample precedent for exploitation of NADH florescence
as an intrinsic probe (e.g. Ref. 30). If one assumes that the
disordered loop adopts the conformation observed in homologous ALDHs, the nicotinamide ring of the NADH is 7 Å from
the site of the mutations and could serve as a reporter group for
conformational differences that affect the NADH binding site
or the environment of any Trp residues within the range for
fluorescence resonance energy transfer. Accordingly, we found
that during catalysis Trp-NADH fluorescence resonance energy transfer is enhanced. Note that in Fig. 3 the protein bound
NADH emission is greater at the excitation wavelength for
NADH (340 nm), whereas when we observe NADH fluorescence from reduced co-factor generated in the course of the
reaction (Fig. 4) the signal is significantly greater at the excitation wavelength of Trp. This may indicate a difference in the
conformation of the enzyme in the ternary (enzyme-co-factorsubstrate) versus binary (enzyme-NADH) complex. Further-

FIG. 4. The increase in fluorescence at wavelengths >420 nm
observed when enzyme:NAD and substrate are mixed under
standard assay conditions (460 nM enzyme, 4 mM NAD). The
substrate here is 250 M octanal. The data were recorded at excitations
wavelengths of 295 and 340 nm. WT, wild type.

more, the fluorescence properties of RalDH2:L458F/N459G differ from that of the wild-type protein. Because the nicotinamide
ring is a sensitive probe of its environment, this observation
could be interpreted as a conformational difference between the
double mutant and wild-type proteins. No such structural differences are observed in comparison of the crystal structures of
the wild-type and loop mutant enzymes (both crystallized with
bound co-factor) as the region in which the mutations were
made is not apparent in either structure.
From Fig 1a it is evident that the mutated amino acids
(459 – 460 in ALDH2 numbering) are not directly involved in
the binding of co-factor in either its oxidized or reduced state.
In addition, the crystal structure of RalDH2:L458F/N459G revealed a native-like structure with no structural aberrations in
the co-factor binding domain. Even when the nicotinamide ring
is positioned for hydride transfer the mutated amino acids are
7 Å from this tip of the outstretched co-factor. Furthermore, the
nicotinamide ring is reported to be mobile in other members of
the superfamily (e.g. Ref. 25). Yet, mutation of amino acids

A Disorder to Order Transition in RalDH2
outside the perimeter of the mobile nicotinamide ring subsite
affects the Km of the enzyme for NAD; the Km for the mutant
enzyme is ⬃6 times that of the native enzyme (Table I). The
conformation that the mutated loop cannot adopt has structural consequences in the NAD binding site. This observation is
consistent with what has been reported by others for bovine
mitochondrial ALDH2 for the corresponding region in that
enzyme. Hurley et al. (15) have found that mutation of Arg-475
in ALDH2 leads to disorder in the co-factor binding region
through a “domino effect.” And Sheikh et al. (22) observe that
mutation of Ser-471 to an alanine results in a 50-fold increase
in the Km for NAD. An even more striking effect of a distal
mutation on the NAD binding site was described for the naturally occurring ALDH2:E487K mutation. The mutation, some
13 Å from the co-factor binding site, results in a ⬃150-fold
increase in the Km for NAD (24, 31). Thus, although a disorder
to order transition may be unique to RalDH2, transmission of
a conformational change from the catalytic domain to the nucleotide binding domain is likely a common feature in this
enzyme family.
A Polyhistidine Tag May Affect Activity Assays—When we
initiated these studies we found that wild-type RalDH2 has
improved catalytic activity for its biological substrate when
prepared without a polyhistidine tag. Previous kinetic data
reported for RalDH2 were obtained from the histidine-tagged
form (8). We chose to redesign the expression construct to
produce the enzyme without the amino-terminal extension and
purify the enzyme by the use of affinity resins for nucleotide
binding proteins as well as ion-exchange and size exclusion
chromatography. The kinetic data for its biologic substrate
retinal obtained from the non-histidine tagged enzyme differs
significantly from that of the enzyme with a histidine tag: our
wild-type RalDH2 has a Vmax of ⬃200 nmol/min/mg for retinal
at 25°. This value is 10 times that reported by Wang et al. (8)
and measured in our lab with the histidine-tagged form. It is
also ⬃50 times the activity reported for the enzyme when
purified as a glutathione-transferase fusion protein and then
cleaved (32). In contrast, the Vmax values for the aliphatic
aldehydes are only modestly improved (e.g. 1080 versus ⬃800
nmol/min/mg for octanal). The data described in this report
were all obtained from wild-type and mutant enzymes purified
by conventional chromatographic methods that exploit affinity
chromatography resins for nucleotide binding proteins. It is not
likely that differences in the enzyme assays utilized are the
source of the discrepancy in the results, as we also see the rate
reported by Wang et al. (8) for the histidine-tagged enzyme
(data not shown) with our experimental approach of monitoring
NADH production by fluorescence. Rather it is more likely that
the difference is a direct result of the fact that the amino
terminus of the protein is positioned near the entrance to the
substrate access channel.
Concluding Remarks—As described above, the substrate access channel in retinaldehyde dehydrogenase type II is not
ordered in the absence of substrate, and it was suggested that
this disorder is functional; a disorder to order transition that
can only be invoked by larger substrates enables substrate
discrimination. We reasoned that such a mechanism could be
tested by site-directed mutagenesis as a region of the polypeptide that remains disordered through the catalytic cycle should
be insensitive to sequence changes if the amino acids mutated
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are not directly involved in substrate binding or catalytic activity. We found that when mutations are introduced in a
disordered loop that is confined to the substrate access channel,
enzyme activity is impaired. This observation indicates that
during the catalytic cycle this region must make a specific
intramolecular contact. We demonstrate that NADH fluorescence properties of the loop mutant and the wild-type enzymes
are distinctly different and suggest that this difference reflects
different environments of the Trp residues within the Förster
distance for fluorescence resonance energy transfer. Thus, although the crystal structure of the mutant enzyme in the
presence of co-factor is essentially identical to that of the native:NAD structure, a conformation of the enzyme that is required for effective catalysis is not as readily accessible to the
RalDH2:L458F/N459G mutant form.
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